These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15470798

  • 1. The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients.
    Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S.
    Pharmacopsychiatry; 2004 Sep; 37(5):200-5. PubMed ID: 15470798
    [Abstract] [Full Text] [Related]

  • 2. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment.
    Hetzel G, Moeller O, Evers S, Erfurth A, Ponath G, Arolt V, Rothermundt M.
    Psychopharmacology (Berl); 2005 Mar; 178(2-3):161-6. PubMed ID: 15316717
    [Abstract] [Full Text] [Related]

  • 3. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
    Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, Frodl T, Mavrogiorgou P, Hegerl U.
    J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
    [Abstract] [Full Text] [Related]

  • 4. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
    Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ.
    Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
    [Abstract] [Full Text] [Related]

  • 5. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
    Moeller O, Hetzel G, Michael N, Rothermundt M, Arolt V, Erfurth A.
    Neuropsychobiology; 2005 Sep; 51(2):67-71. PubMed ID: 15741746
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study.
    Kerestes R, Labuschagne I, Croft RJ, O'Neill BV, Bhagwagar Z, Phan KL, Nathan PJ.
    Psychopharmacology (Berl); 2009 Mar; 202(4):621-34. PubMed ID: 18825371
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression.
    Quednow BB, Kühn KU, Stelzenmuelle R, Hoenig K, Maier W, Wagner M.
    Psychopharmacology (Berl); 2004 Oct; 175(4):399-406. PubMed ID: 15042278
    [Abstract] [Full Text] [Related]

  • 10. Treatment effects of serotonergic and noradrenergic antidepressants on the intensity dependence of auditory ERP components in major depression.
    Linka T, Sartory G, Wiltfang J, Müller BW.
    Neurosci Lett; 2009 Sep 29; 463(1):26-30. PubMed ID: 19616062
    [Abstract] [Full Text] [Related]

  • 11. Citalopram plus reboxetine in treatment-resistant depression.
    Devarajan S, Dursun SM.
    Can J Psychiatry; 2000 Jun 29; 45(5):489-90. PubMed ID: 10900531
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
    Takahashi E, Katayama M, Niimi K, Itakura C.
    Eur J Pharmacol; 2008 Jul 28; 589(1-3):149-56. PubMed ID: 18571641
    [Abstract] [Full Text] [Related]

  • 18. Oral citalopram and reboxetine challenge tests before and after selective antidepressant treatment.
    Moeller O, Hetzel G, Rothermundt M, Michael N, Nyhuis PW, Suslow T, Arolt V, Erfurth A.
    J Psychiatr Res; 2003 Jul 28; 37(3):261-2. PubMed ID: 12650745
    [No Abstract] [Full Text] [Related]

  • 19. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
    Aragona M, Bancheri L, Perinelli D, Tarsitani L, Pizzimenti A, Conte A, Inghilleri M.
    Eur J Pain; 2005 Feb 28; 9(1):33-8. PubMed ID: 15629872
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression.
    Wagner G, Koch K, Schachtzabel C, Sobanski T, Reichenbach JR, Sauer H, Schlösser RG.
    J Psychiatry Neurosci; 2010 Jul 28; 35(4):247-57. PubMed ID: 20598238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.